

BIO OSMO BHD (740838-A)
(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE QUARTER AND YEAR ENDED 30 JUNE 2017

RM'000	3 months ended			12 months ended		
	30.06.17 (Unaudited)	30.06.16 (Unaudited)	Changes (%)	30.06.17 (Unaudited)	30.06.16 (Unaudited)	Changes (%)
Revenue	2,787	1,832	52.13	9,111	6,169	47.69
Other income	(58)	(19)	205.26	561	1,691	(66.82)
Operating expenses	(7,594)	(4,405)	72.40	(20,027)	(13,227)	51.41
Operating loss before tax	<u>(4,865)</u>	<u>(2,592)</u>	87.69	<u>(10,355)</u>	<u>(5,367)</u>	92.94
Taxation	(919)	-	100.00	(1,212)	-	100.00
Net loss after tax	<u>(5,784)</u>	<u>(2,592)</u>	123.15	<u>(11,567)</u>	<u>(5,367)</u>	115.52
Total comprehensive expense for the period	<u>(5,784)</u>	<u>(2,592)</u>	123.15	<u>(11,567)</u>	<u>(5,367)</u>	115.52
(Loss)/profit attributable to:						
Owners of the Company	(5,717)	(2,531)	125.88	(11,454)	(5,050)	126.81
Non-controlling interest	<u>(67)</u>	<u>(61)</u>	9.84	<u>(113)</u>	<u>(317)</u>	(64.35)
	<u>(5,784)</u>	<u>(2,592)</u>	123.15	<u>(11,567)</u>	<u>(5,367)</u>	115.52
Total comprehensive (expense)/income attributable to:						
Owners of the Company	(5,717)	(2,531)	125.88	(11,454)	(5,050)	126.81
Non-controlling interest	<u>(67)</u>	<u>(61)</u>	9.84	<u>(113)</u>	<u>(317)</u>	(64.35)
	<u>(5,784)</u>	<u>(2,592)</u>	123.15	<u>(11,567)</u>	<u>(5,367)</u>	115.52
Loss per share attributable to Owners of the Company (sen):-						
Basic	(0.77)	(0.51)	51.61	(1.75)	(1.01)	72.39
Fully diluted*	<u>(0.77)</u>	<u>(0.51)</u>	51.61	<u>(1.75)</u>	<u>(1.01)</u>	72.39

* The diluted loss per share of the Group is equivalent to the basic loss per share as the diluted loss per share has anti-dilutive effect.

The above condensed consolidated statements of profit or loss and other comprehensive income should be read in conjunction with the audited financial statements for the financial year ended 30 June 2016 and the accompanying explanatory notes attached to these interim financial statements.

BIO OSMO BHD (740838-A)
(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION AS AT 30 JUNE 2017

RM'000	As at 30.06.17 (Unaudited)	As at 30.06.16 (Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	22,898	13,346
Intangible assets	11,740	-
Other receivables	400	-
	<u>35,038</u>	<u>13,346</u>
Current assets		
Inventories	574	411
Trade receivables	4,969	848
Other receivables, deposits and prepayments	1,704	960
Tax recoverable	55	55
Fixed deposits with licensed bank	306	306
Cash on hand and at banks	2,033	625
Asset classified as held for sale	-	11,540
	<u>9,641</u>	<u>14,745</u>
TOTAL ASSETS	<u><u>44,679</u></u>	<u><u>28,091</u></u>
EQUITY AND LIABILITIES		
Share capital	42,299	24,933
Accumulated losses	(13,210)	(3,023)
Other reserves	-	2,381
Equity attributable to Owners of the Company	29,089	24,291
Non-controlling interest	4,819	(1,103)
TOTAL EQUITY	<u>33,908</u>	<u>23,188</u>
Non-current liabilities		
Other payables	81	-
	<u>81</u>	<u>-</u>
Current liabilities		
Trade payables	1,835	509
Other payables and accruals	7,936	4,394
Tax payable	919	-
TOTAL LIABILITIES	<u>10,690</u>	<u>4,903</u>
TOTAL EQUITY AND LIABILITIES	<u><u>44,679</u></u>	<u><u>28,091</u></u>
Net assets per share attributable to owners of the Company (RM)	<u>0.03</u>	<u>0.05</u>

The above condensed consolidated statements of financial position should be read in conjunction with the audited financial statements for the financial year ended 30 June 2016 and the accompanying explanatory notes attached to these interim financial statements.

BIO OSMO BHD (740838-A)
(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY FOR THE YEAR ENDED 30 JUNE 2017

	<----- Attributable to Owners of the Company ----->				Total	Non- controlling Interest	Total Equity
	Share Capital	Distributable	<----- Non-Distributable ----->				
		Accumulated losses	Share Premium	Warrants Reserve			
	RM '000	RM '000	RM '000	RM '000	RM '000	RM '000	RM '000
Balance as of 1 July 2016	24,933	(3,023)	288	2,093	24,291	(1,103)	23,188
Issuance of shares	17,366	-	-	-	17,366	-	17,366
Share issuance expenses	-	(826)	(288)	-	(1,114)	-	(1,114)
Acquisition of subsidiary	-	-	-	-	-	6,035	6,035
Warrants expiry	-	2,093	-	(2,093)	-	-	-
Total comprehensive expense for the period	-	(11,454)	-	-	(11,454)	(113)	(11,567)
Balance as of 30 June 2017	42,299	(13,210)	-	-	29,089	4,819	33,908
<hr/>							
Balance as of 1 July 2015	99,732	(72,772)	288	2,093	29,341	(786)	28,555
Total comprehensive expense for the period	-	(5,050)	-	-	(5,050)	(317)	(5,367)
Par value reduction	(74,799)	74,799	-	-	-	-	-
Balance as of 30 June 2016	24,933	(3,023)	288	2,093	24,291	(1,103)	23,188

The above condensed consolidated statements of changes in equity should be read in conjunction with the audited financial statements for the financial year ended 30 June 2016 and the accompanying explanatory notes attached to these interim financial statements.

BIO OSMO BHD (740838-A)
(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEAR ENDED 30 JUNE 2017

RM'000	12 months ended	
	30.06.17	30.06.16
	(Unaudited)	(Unaudited)
CASH FLOWS USED IN OPERATING ACTIVITIES		
Loss before taxation	(10,355)	(5,367)
Adjustments for:		
Bad debts written off	4	-
Amortisation of intangible assets	571	-
Deposits written off	75	-
Depreciation of property, plant and equipment	1,988	2,303
Impairment loss on property, plant and equipment	4,102	760
Impairment loss on receivables	179	839
Property, plant and equipment written off	254	-
Gain on disposal of property, plant and equipment	(460)	(1,505)
Interest income	(21)	(5)
Unrealised gain on foreign currency exchange	(28)	(6)
Operating loss before working capital changes	(3,691)	(2,981)
(Increase)/decrease in inventories	(163)	169
(Increase)/decrease in receivables	(4,367)	1,641
Decrease in payables	(2,040)	(1,884)
Cash absorbed by operations	(10,261)	(3,055)
Income tax paid	(365)	-
Net cash used in operating activities	(10,626)	(3,055)
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of property, plant and equipment	(3,396)	(136)
Proceeds from disposal of property, plant and equipment	12,000	3,000
Cash outflow on acquisition of a subsidiary company	(12,850)	-
Net cash (used in)/from investing activities	(4,246)	2,864
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from issuance of ordinary shares	17,366	-
Shares issuance expenses paid	(1,114)	-
Net cash from financing activities	16,252	-
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS	1,380	(191)
EFFECT OF EXCHANGE RATE CHANGES	28	6
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	625	810
CASH AND CASH EQUIVALENTS AT END OF PERIOD	2,033	625
CASH AND CASH EQUIVALENTS AT END OF THE FINANCIAL PERIOD COMPRISE:		
Cash and bank balances	2,033	625
Fixed deposit with licensed banks	306	368
	2,339	993
Less : Fixed deposit pledged to licensed banks	(306)	(368)
	2,033	625

The above condensed consolidated statements of cash flows should be read in conjunction with the audited financial statements for the financial year ended 30 June 2016 and the accompanying explanatory notes attached to these interim financial statements.

BIO OSMO BHD (740838-A)
(Incorporated in Malaysia)

NOTES TO THE QUARTERLY REPORT ON CONSOLIDATED RESULT FOR THE QUARTER AND YEAR ENDED 30 JUNE 2017

A1. BASIS OF PREPARATION

This condensed consolidated interim financial statements (Condensed Report), other than for financial instruments, have been prepared under the historical cost convention. Certain financial instruments have been carried at fair value in accordance to Malaysian Financial Reporting Standard (MFRS) 139 Financial Instruments: Recognition and Measurement.

This condensed consolidated interim financial statements (Condensed Report) have been prepared in accordance with MFRS 134: Interim Financial Reporting and paragraph 9.22 of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad.

This Condensed Report should be read in conjunction with the audited financial statements for the financial period ended 30 June 2016. The explanatory notes attached to the Condensed Report provide an explanation of events and transactions that are significant to an understanding of the changes in the financial position and performance of the Group since the financial year ended 30 June 2016.

A2. SIGNIFICANT ACCOUNTING POLICIES

The accounting policies adopted in the preparation of the Condensed Report are consistent with those followed in the preparation of the Group's audited financial statements for the financial period ended 30 June 2016.

Adoption of Amendments to Standards and IC Interpretations

The Group has adopted the following Amendments to Standards and IC Interpretations, with a date of initial application of 1 January 2016.

MFRS 14	Regulatory Deferral Accounts
Amendments to MFRS 11	Accounting for Acquisitions of Interest in Joint Operations
Amendments to MFRS 101	Presentation of Financial Statements - Disclosure Initiative
Amendments to MFRS 127	Equity Method in Separate Financial Statements
Amendments to MFRS 10 and MFRS 128	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture
Amendments to MFRS 116 and MFRS 138	Clarification of Acceptable Methods of Depreciation and Amortisation
Amendments to MFRS 116 and MFRS 141	Property, plant and equipment - Agriculture: Bearer Plants
Amendments to MFRS 10, MFRS 12 and MFRS 128	Investment Entities: Applying the Consolidation Exception
Annual Improvements to MFRSs 2012 - 2014 Cycle	

The adoption of the above pronouncements did not have any impact on the financial statements of the Group.

BIO OSMO BHD (740838-A)
(Incorporated in Malaysia)

A2. SIGNIFICANT ACCOUNTING POLICIES (CONT'D)

Standards issued but not yet effective

At the date of authorisation of the Condensed Report, the following Standards, Amendments and Annual Improvements to Standards were issued by the Malaysian Accounting Standards Board (MASB) but are not yet effective and have not been adopted by the Group:

Standards issued but not yet effective (cont'd)

Effective for financial periods beginning on or after 1 January 2017

Amendments to MFRS 107	Statement of Cash Flows - Disclosure Initiative
Amendments to MFRS 112	Income Taxes - Recognition of Deferred Tax Assets for Unrealised Losses
Amendments to MFRS 12	Disclosure of Interests in Other Entities (Annual Improvements to MFRSs 2014 - 2016 Cycle)

Effective for financial periods beginning on or after 1 January 2018

Amendments to MFRS 2	Share-based Payment - Classification and Measurement of Share-based Payment Transactions
Amendments to MFRS 4	Insurance Contracts - Applying MFRS 9 Financial Instruments with MFRS 4 Insurance Contracts
Amendments to MFRS 140	Investment Property - Transfers of Investment Property
Amendments to MFRS 1	First-time Adoption of Malaysian Financial Reporting Standards (Annual Improvements to MFRSs 2014 - 2016 Cycle)
Amendments to MFRS 128	Investments in Associates and Joint Ventures (Annual Improvements to MFRSs 2014 - 2016 Cycle)
IC Interpretations 22	Foreign Currency Transactions and Advance Consideration

Effective for financial periods beginning on or after 1 January 2019

MFRS 16	Leases
---------	--------

The Group will adopt the above pronouncements when they become effective in the respective financial periods. The Group does not expect any material impact to the financial statements on the above pronouncements other than described below, for which the effects are still being assessed:

Amendments to MFRS 107 Statement of Cash Flows - Disclosure Initiative

These amendments to MFRS 107 Statement of Cash Flows require the entity to disclose a reconciliation between the opening and closing balances for liabilities arising from financing activities, including both changes arising from cash flows and non-cash flow changes. The adoption of these amendments affects only the disclosure notes to the financial statements and has no financial impact on the Group's financial statements.

A3. AUDITORS' REPORT ON PRECEDING ANNUAL FINANCIAL STATEMENTS

The preceding financial period's audited financial statements of the Group were not subject to any qualification.

A4. SEASONAL AND CYCLICAL FACTORS

The business operations of the Group are subject to the forces of supply and demand, and thus could display cyclical trends.

BIO OSMO BHD (740838-A)
(Incorporated in Malaysia)

A5. UNUSUAL ITEMS AFFECTING ASSETS, LIABILITIES, EQUITY, NET INCOME OR CASH FLOWS

There were no material items of an unusual nature and amount for the current quarter and year ended 30 June 2017 under review.

A6. MATERIAL ESTIMATES AND CHANGES IN ESTIMATES

There were no material changes in the estimates used in the current quarter and year ended 30 June 2017.

A7. ISSUANCES, CANCELLATIONS, REPURCHASES, RESALE AND REPAYMENTS OF DEBT AND EQUITY SECURITIES

There was no issuance and repayment of debt and equity securities, share buy-backs, share cancellations and resale of treasury shares for the current quarter and year ended 30 June 2017 other than issuance of 224,397,000 new ordinary shares at RM 0.05 each to three individual subscribers under the Private Placement arrangement on 26 October 2016. Subsequently, the Company had on 29 March 2017 announced to implement a private placement of up to 10% of the share capital of the Company. On 18 May 2017, Bursa approved the listing of and quotation for up to 72,305,700 new ordinary shares in the Company and the private placement was completed on 6 June 2017.

A8. DIVIDEND PAID

There were no dividends paid during the current and previous corresponding quarter.

A9. SEGMENTAL INFORMATION

MFRS 8 requires separate reporting of segmental information for operating segments. Operating segments reflect the Group's management structure and the way financial information is regularly reviewed by the top management and the Board of Directors.

The Group is focused in 2 areas of activities, bottled drinking water business and hospitality business. The new hospitality business includes businesses of management and operation of hotels and resorts, property investment and hotel development.

<u>Segment Revenue and Results</u> RM '000	3 months ended		12 months ended	
	30.06.17	30.06.16	30.06.17	30.06.16
Revenue				
- Bottled water	140	1,832	4,407	6,169
- Hospitality (post acquisition result since 28 October 2016)	2,647	-	4,704	-
	<u>2,787</u>	<u>1,832</u>	<u>9,111</u>	<u>6,169</u>
Net (loss)/profit after tax				
- Bottled water	(5,630)	(2,592)	(10,090)	(5,367)
- Hospitality (post acquisition result since 28 October 2016)	1,485	-	2,129	-
- other unallocated expenses	(1,639)	-	(3,606)	-
	<u>(5,784)</u>	<u>(2,592)</u>	<u>(11,567)</u>	<u>(5,367)</u>

BIO OSMO BHD (740838-A)
(Incorporated in Malaysia)

A9. SEGMENTAL INFORMATION (CONT'D)

Hospitality

The newly acquired hospitality business, via Intra Magnum Sdn Bhd (IMSB) is contributing positive performance to the Group. For the 10-month period starting from the completion of the subscription of a 75% stake on 28 October 2016 to 30 June 2017, IMSB chalked in a revenue of RM4.70 million, derived from the technical consultancy fee for the pre-development project of Impiana Cherating Hotel & Resort and Impiana Ubud Resort in Bali; and the hotel management fee from Impiana Hotel Ipoh. The 10-month contribution from the Hospitality Segment has accounted for approximately 52% of the Group's revenue for FYE 30 June 2017.

The Hospitality Segment recorded profit after tax of RM2.13 million, after recognising RM0.57 million in amortisation of intangible assets and RM0.85 million in taxation. This Segment enjoyed net profit margin over 45% during the period.

Bottled water

The bottled water segment experienced a 28.6% drop in revenue to RM4.41 million during the financial year ended 30 June 2017, compared to the same period in FYE 30 June 2016. This is on the back of a 9.1% rise in average monthly sales volume during the corresponding period.

For the 4Q period, spanning from 1 April to 30 June 2017, the bottled water segment posted a lower revenue of RM0.14 million, compared to RM1.83 million during the previous year's corresponding quarter. The drop was because the bulk of the sales of bottled water during the period was passed through a third party distributor on a "cost plus" basis. As a result, the contribution from bottled water segment has reduced to 48% of the Group revenue during the financial year.

Holding Company

At the holding company level, there were an "unallocated expenses" amounting to RM3.61 million during the financial year. There were mainly operating costs at the holding company, coupled with professional fees incurred during the financial year, related to the IMSB corporate exercise which was completed in 2016 as well as the private placement exercise during the fourth quarter of FY2017.

A10. VALUATION OF PROPERTY, PLANT AND EQUIPMENT

There were no revaluation of property, plant and equipment during the quarter and year ended 30 June 2017.

A11. EVENTS AFTER THE REPORTING PERIOD

There was no material event subsequent to the end of the reporting period for the quarter and year ended 30 June 2017.

BIO OSMO BHD (740838-A)
(Incorporated in Malaysia)

A12. RELATED PARTY TRANSACTION

Significant transaction between the Group with the related parties during the quarter and year ended 30 June 2017 were as follows:

RM '000	3 months ended		12 months ended	
	30.06.17	30.06.16	30.06.17	30.06.16
Hotel management and technical fees received from:				
- Impiana Hotel Ipoh Sdn. Bhd.	85	-	85	-
- Impiana Cherating Sdn. Bhd.	2,359	-	2,359	-
- Impiana Ubud (Labuan) Co. Ltd.	203	-	203	-

The transactions were entered in the normal course of business and have been established under normal commercial terms that are no less favourable than those arranged with independent third parties.

A13. CHANGES IN THE COMPOSITION OF THE GROUP

There were no changes in the composition of the Group during the quarter and year ended 30 June 2017, other than the subscription of a 75% equity interest in Intra Magnum Sdn Bhd ("IMSB") and hence, IMSB became a subsidiary of the Group.

A14. CONTINGENT LIABILITIES AND CONTINGENT ASSETS

There were no contingent liabilities and assets as at the date of this report.

A15. CAPITAL COMMITMENT

There were no capital commitment by the Group during the financial period under review.

BIO OSMO BHD (740838-A)
(Incorporated in Malaysia)

ADDITIONAL INFORMATION REQUIRED BY THE LISTING REQUIREMENTS OF BURSA SECURITIES

B1. REVIEW OF PERFORMANCE

For the current quarter under review, the Group registered a group revenue of RM2.787 million versus RM1.832 million recorded in the Fourth Quarter of the previous financial year, an improvement of 52.1% on a year-on-year comparison. The rise in revenue during the quarter was mainly supported by contribution from the Hospitality Segment, which accounted for the majority of Group revenue during the quarter under review. The income streams from this segment were derived from hotel management fee and technical consultancy fee of new hotel resort projects.

Net loss during the quarter increased to RM5.784 million, compared to RM2.592 million during the corresponding period last year. The increase in net loss was mainly due to the amortisation of intangible assets and non-recurring impairment of property, plant and equipment, as well as professional fees incurred for corporate exercises undertaken during the financial year.

There were some non-cash adjustments during the financial year, such as RM4.10 million for impairment of property, plant and equipment, RM1.99 million for depreciation charges; RM0.57 million for amortisation of intangible assets at the hotel management contracts. Excluding these adjustments, which totalled RM6.66 million and the one-off repair and maintenance costs incurred at the bottled water plant of RM1.89 million during the financial year, the Group would have recorded much lower operating loss of RM4.76million.

B2. MATERIAL CHANGES IN LOSS BEFORE TAXATION AGAINST THE IMMEDIATE PRECEDING QUARTER

Variation of results against preceding quarter

	Current Quarter 30.06.17 RM'000	Immediate Preceding Quarter 31.03.17 RM'000	Changes %
Revenue	2,787	2,382	17.00
Loss before tax	(4,865)	(3,273)	48.64
Loss after tax	(5,784)	(3,379)	71.17
Loss attributable to owners of the Company	(5,717)	(3,385)	68.89

For the current quarter under review, Group revenue increased by 17% to RM2.787 million vis-à-vis RM2.382 million recorded during the preceding quarter. The slight increase in revenue was due to higher demand in hotel management business, particularly during the Hari Raya festive season in June 2017. Loss After Taxation was higher at RM5.784 million, compared to RM3.379 million previously due to the amortisation of intangible assets and non-recurring impairment of property, plant and equipment, as well as professional fees incurred for corporate exercises undertaken during the financial year.

B3. CURRENT PROSPECTS

The Group is confident to see remarkable performance from the Hospitality Segment, which is gearing to become the major revenue and earnings contributor for the group and to support the overall growth of the Group.

The re-development works of Impiana Cherating Resort in the state of Pahang and Impiana Ubud in Bali will intensify in the coming year, which will translate to better technical consultancy fees for IMSB. Occupancy at Impiana Ipoh Hotel is poised to stabilise going forward, thanks to the gradual completion of the bulk of the upgrading works.

For the Bottled Water segment, the capex and repair & maintenance works on the bottled drinking water plant which was embarked since early 2017 is expected to see improvements in the coming financial year. The replacement of certain obsolete and unusable equipment will ensure the readiness of the plant to generate higher production volume.

BIO OSMO BHD (740838-A)
(Incorporated in Malaysia)

B4. PROFIT FORECAST

There was no profit forecast for the period under review was required.

B5. LOSS BEFORE TAXATION

Loss before taxation have been determined after charging/(crediting) amongst other items the following:-

RM '000	3 months ended		12 months ended	
	30.06.17	30.06.16	30.06.17	30.06.16
Amortisation of intangible assets	571	-	571	-
Bad debts written off	4	-	4	-
Deposits written off	75	-	75	-
Depreciation of property, plant and equipment	557	577	1,988	2,303
Impairment loss on receivables	179	839	179	839
Impairment loss on property, plant and equipment	4,102	760	4,102	760
(Gain)/loss on foreign currency exchange:				
- unrealised	(28)	26	(28)	(6)
- realised	2	2	(18)	(76)
Gain on disposal of property, plant and equipment	-	(1)	(460)	(1,505)
Property, plant and equipment written off	254	-	254	-
Interest income	-	-	(21)	(5)

Other than the above, the items listed under Appendix 9B Note 16 of the Listing Requirement of Bursa Malaysia Securities Berhad are not applicable.

B6. TAXATION

RM '000	3 months ended		12 months ended	
	30.06.17	30.06.16	30.06.17	30.06.16
Income Tax				
- current period expense	919	-	1,212	-
	919	-	1,212	-

Domestic income tax is calculated at the Malaysian statutory income tax rate of 24% of the estimated assessable profit for the financial period.

B7. ACCUMULATED LOSSES

RM '000	As at	As at
	30.06.17	30.06.16
Realised	(52,407)	(41,198)
Unrealised	28	(1,966)
	(52,379)	(43,164)
Consolidation adjustments	39,169	40,141
Total accumulated losses	(13,210)	(3,023)

BIO OSMO BHD (740838-A)
(Incorporated in Malaysia)

B8. CORPORATE PROPOSAL

The Group did not have any corporate proposal as at the end of the reporting period.

B9. GROUP BORROWINGS

The Group did not have any borrowings as at the end of the reporting period.

B10. STATUS OF UTILISATION OF PROCEEDS

The proceeds from the new placement of new ordinary shares of RM 6.146 million (72,305,700 ordinary shares of RM 0.085 each), completed on 6 June 2017, are to be utilised as follows:

Purpose	Proposed utilisation as per announcement dated 29 March 2017	Actual utilisation as at 30 June 17	Intended timeframe for utilisation	Balance unutilised	
	RM'000	RM'000		RM'000	%
- Working capital	4,286	3,833	Within 24 months	453	7.37
- Business expansion	1,594	468	Within 24 months	1,126	18.32
- Estimated expenses in relation to proposed private placement	266	266	Within 1 month	-	-
TOTAL	6,146	4,567		1,579	25.69

B11. MATERIAL LITIGATION

The Group did not have any material litigation as at the end of the reporting period.

B12. DERIVATIVE FINANCIAL INSTRUMENT

The Group did not have any derivative financial instrument as at the end of the reporting period.

B13. OFF BALANCE SHEET FINANCIAL INSTRUMENT

As at the end of the financial period and up to the date of this announcement, there is no off balance sheet financial instrument which has a material impact to the financial statement under review.

B14. DIVIDEND PAYABLE

No interim dividend has been declared for the current financial period to date.

B15. LOSS PER SHARE ("LPS")

	3 months ended		12 months ended	
	30.06.17	30.06.16	30.06.17	30.06.16
Net loss attributable to Owners of the Company (RM '000)	(5,717)	(2,531)	(11,454)	(5,050)
Weighted average number of ordinary shares in issue ('000)	742,921	498,660	656,079	498,660
Basic LPS (sen)	(0.77)	(0.51)	(1.75)	(1.01)
Diluted LPS (sen)	(0.77)	(0.51)	(1.75)	(1.01)

B16. AUTHORISED FOR ISSUE

The condensed consolidated interim financial statements were authorised for issue by the Board of Directors in accordance with a resolution of the Directors on 29 August 2017.